Anika Therapeutics (ANIK) Key Ratios

$20.81

up-down-arrow $-0.19 (-0.90%)

As on 04-Sep-2026 16:01EDT

Market cap

info icon

$279 Mln

Revenue (TTM)

info icon

$121 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

2

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue 10.12 15.56 31.36 -9.38 -2.48
EBIT 170.11 185.22 72.85 23.67 12.93
Net Profit 165.45 183.35 93.76 22.30 14.39
EPS 165.94 189.15 93.49 22.15 11.23
Book Value -- -- -6.50 -20.56 -12.51
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-25Dec-24
EBIT-Margin info -2.65-6.57-2.41-8.25-2.31
Net Margin info -----3.14----
Return on equity info -23.77-15.01-2.70-7.32-30.79
Return on Capital info -20.93-13.24---6.22-26.85
Return on Assets info -18.68-11.83-1.85-5.54-23.82
Debt to Equity (x) info ----0.000.180.17
ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Anika Therapeutics (ANIK)
--
-6.22
-26.85
-29.71
-4.76
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

-2.70

Lower than Peers by 21.67

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Anika Therapeutics (ANIK)
-2.70
-7.32
-30.79
-33.21
-5.19
Peer Median
18.97
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-1.85

Lower than Peers by 4.71

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Anika Therapeutics (ANIK)
-1.85
-5.54
-23.82
-26.68
-4.27
Peer Median
2.86
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

-2.41

Lower than Peers by 18.23

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Anika Therapeutics (ANIK)
-2.41
-8.25
-2.31
2.61
-12.42
Peer Median
15.82
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

-3.14

Lower than Peers by 11.37

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Anika Therapeutics (ANIK)
-3.14
-9.64
-47.02
-68.44
-9.51
Peer Median
8.23
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

0.00

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Anika Therapeutics (ANIK)
0.00
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Revenue Growth

31.36

Higher than Peers by 23.31

Year on year growth in net sales

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Anika Therapeutics (ANIK)
31.36
-0.06
-0.01
-0.23
0.06
Peer Median
8.05
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

72.85

Higher than Peers by 64.59

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Anika Therapeutics (ANIK)
72.85
-236.72
-187.58
116.27
-4.98
Peer Median
8.26
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

93.76

Higher than Peers by 86.03

Year on year growth in profit after tax

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Anika Therapeutics (ANIK)
93.76
80.70
31.79
-456.34
-459.43
Peer Median
7.73
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

93.49

Higher than Peers by 83.09

Year on year growth in earnings per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Anika Therapeutics (ANIK)
93.49
0.81
0.32
-4.56
-4.54
Peer Median
10.39
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

-0.57

Lower than Peers by 5.45

Year on year growth in book value per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Anika Therapeutics (ANIK)
-0.57
--
--
--
--
Peer Median
4.87
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Anika Therapeutics (ANIK)
--
0.18
0.17
0.13
0.11
Peer Median
0.60
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

--

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Anika Therapeutics (ANIK)
--
0.01
0.01
0.01
0.01
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

4.48

Higher than Peers by 2.83

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Anika Therapeutics (ANIK)
4.48
4.72
4.88
5.26
6.07
Peer Median
1.65
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

3.19

Higher than Peers by 1.99

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Anika Therapeutics (ANIK)
3.19
3.86
3.85
4.47
4.65
Peer Median
1.20
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

-0.46

Lower than Peers by 5.23

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Anika Therapeutics (ANIK)
-0.46
-5.34
-1.18
1.37
-29.66
Peer Median
4.77
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

24.09

Higher than Peers by 2.81

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Anika Therapeutics (ANIK)
24.09
21.00
19.68
21.82
22.16
Peer Median
21.27
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.59

Higher than Peers by 0.19

Sales / Average Total Assets

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Anika Therapeutics (ANIK)
0.59
0.57
0.51
0.39
0.45
Peer Median
0.40
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Anika Therapeutics (ANIK)
--
76.54
76.08
92.21
75.36
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Anika Therapeutics (ANIK)
--
158.72
200.63
306.41
220.85
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Anika Therapeutics (ANIK)
--
43.44
49.12
72.88
48.69
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Anika Therapeutics (ANIK)
--
191.82
227.58
325.74
247.52
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Earnings

--

--

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Anika Therapeutics (ANIK)
--
-12.96
-4.30
-4.01
-29.16
Peer Median
37.91
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

2.05

Lower than Peers by 5.64

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Anika Therapeutics (ANIK)
2.05
0.98
1.57
1.56
1.52
Peer Median
7.69
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Anika Therapeutics (ANIK)
--
--
--
--
--
Peer Median
0.56
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

523.47

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Anika Therapeutics (ANIK)
523.47
-30.67
39.69
16.74
-69.87
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

278

Lower than Peers by 2,291

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Anika Therapeutics (ANIK)
278
--
--
--
--
Peer Median
2,569
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...